Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 6/20 | 0.80 |
| ▸ | MAPT | P10636 | 6/20 | 0.75 |
| ▸ | POLB | P06746 | 2/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455859 | 0.88 | MAPT (0.81) | FLT3MAPTPOLBL3MBTL1TP53 | |
| SCHEMBL15347034 | 0.85 | POLB (0.81) | MAPTPOLBTP53ALDH1A1KDM4E | |
| SCHEMBL13183042 | 0.85 | FLT3 (0.74) | FLT3MAPTPOLBL3MBTL1TP53 | |
| SCHEMBL3397527 | 0.83 | FLT3 (0.71) | FLT3MAPTPOLBL3MBTL1TP53 | |
| SCHEMBL5453222 | 0.82 | FLT3 (1.00) | FLT3MAPTL3MBTL1TP53NPC1 | |
| SCHEMBL8289835 | 0.82 | FLT3 (0.71) | FLT3MAPTPOLBL3MBTL1NPC1 | |
| SCHEMBL8290601 | 0.82 | L3MBTL1 (0.72) | FLT3MAPTL3MBTL1TP53RAB9A | |
| SCHEMBL31074960 | 0.81 | RAB9A (0.77) | MAPTPOLBNPC1RAB9AALDH1A1 | |
| SCHEMBL34468495 | 0.81 | FLT3 (0.66) | FLT3MAPTPOLBL3MBTL1TP53 | |
| SCHEMBL3397102 | 0.81 | L3MBTL1 (0.67) | FLT3MAPTPOLBL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | FLT3 3509/4885MAPT 21/4885POLB 404/4885 |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | NCOA4, SREBF1, ACOX1 | FLT3 1273/4885MAPT 2945/4885POLB 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.